StoxCipla vs Mankind Pharma: share price & financials comparison
NSE: CIPLA vs MANKIND · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Cipla vs Mankind Pharma at a glance
Cipla (CIPLA) has a market capitalisation of ₹1,13,988 Cr, against ₹1,04,902 Cr for Mankind Pharma (MANKIND). Over the past year Mankind Pharma has returned +3.9%, compared with -10.8% for Cipla. On valuation, Cipla trades at a lower P/E of 39.3 versus 46.7. Mankind Pharma earns a higher return on equity (12.8% vs 8.2%). Cipla comes out ahead on size, valuation and financial health. Mankind Pharma comes out ahead on profitability, growth, momentum and technicals. Across the scored metrics below, Cipla leads on 6 and Mankind Pharma on 10. On StoxGud's 10-point checklist, Cipla scores 6/10 and Mankind Pharma scores 7/10.
| Metric | Cipla | Mankind Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,13,988 Cr | ₹1,04,902 Cr |
| Revenue (latest FY) | ₹28,163 Cr | ₹14,278 Cr |
| Net profit (latest FY) | ₹3,879 Cr | ₹1,913 Cr |
| Valuation | ||
| P/E | 39.3 | 46.7 |
| P/B | 3.22 | 5.97 |
| Dividend yield | 1.13% | 0.04% |
| Profitability | ||
| Return on equity | 8.2% | 12.8% |
| Net profit margin | 10.3% | 14.6% |
| Operating margin | 17.0% | 26.5% |
| Growth | ||
| Revenue growth (YoY) | -2.4% | +17.3% |
| Net profit growth (YoY) | -35.1% | +39.1% |
| Revenue CAGR (multi-year) | +8.0% | +17.7% |
| Financial health | ||
| Debt to equity | 0.01 | 0.31 |
| Momentum | ||
| 1-month return | +6.3% | +1.6% |
| 1-year return | -10.8% | +3.9% |
| 3-year CAGR | +5.4% | +13.0% |
| 5-year CAGR | +9.1% | — |
| 10-year CAGR | +10.0% | — |
| Distance from 52W high | -8.4% | -3.0% |
| Technicals | ||
| RSI (14) | 82 | 72 |
| Price vs 200-day avg | +3.5% | +9.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Cipla | Mankind Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 6/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Cipla or Mankind Pharma?
Cipla has a market cap of ₹1,13,988 Cr and Mankind Pharma has a market cap of ₹1,04,902 Cr as of 06 Nov 2026.
Which has a lower P/E, Cipla or Mankind Pharma?
Cipla has the lower P/E: Cipla trades at 39.3 and Mankind Pharma at 46.7.
Which gave better returns in the last year, Cipla or Mankind Pharma?
Mankind Pharma did better: Cipla returned -10.8% and Mankind Pharma returned +3.9% over one year.
Is Cipla or Mankind Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Cipla scores 6/10 and Mankind Pharma scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.